biologic

Zynlonta

loncastuximab tesirine-lpyl

Loss of exclusivityApril 2033projected — 12-year biologic exclusivity estimate

CompanyADC Therapeutics →View the full company profile on CliffBio

Drug detail

Brand name	Zynlonta
Active ingredient	loncastuximab tesirine-lpyl
Strength	10MG
Dosage form	For Injection
Route	Intravenous
Modality	Biologic
FDA approval	April 2021
Marketing status	Rx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.